

1 **DIVISION E—EXTENSION OF**
2 **AGRICULTURAL PROGRAMS**

3 **SEC. 5001. UNITED STATES GRAIN STANDARDS ACT EXTEN-**
4 **SION.**

5 (a) Sections 7(j)(5), 7A(l)(4), and 21(e) of the United
6 States Grain Standards Act (7 U.S.C. 79(j)(5), 79a(l)(4),
7 87j(e)) shall be applied by substituting “January 30,
8 2026” for “September 30, 2025” each place it appears.

9 (b) Sections 7D and 19(a) of the United States Grain
10 Standards Act (7 U.S.C. 79d, 87h(a)) shall be applied by
11 substituting “2026” for “2025” each place it appears.

12 **SEC. 5002. EXTENSION OF AGRICULTURAL PROGRAMS.**

13 (a) EXTENSION.—

14 (1) IN GENERAL.—Except as otherwise pro-
15 vided in this section and the amendments made by
16 this section, notwithstanding any other provision of
17 law, the authorities (including any limitations on
18 such authorities) provided by each provision of the
19 Agriculture Improvement Act of 2018 (Public Law
20 115–334; 132 Stat. 4490) and each provision of law
21 amended by that Act (and for mandatory programs
22 at such funding levels) as in effect (including pursu-
23 ant to section 4101 of division D of the American

1 Relief Act, 2025 (Public Law 118–158; 138 Stat.
2 1767)) on September 30, 2025, shall continue and
3 be carried out until the date specified in paragraph
4 (2).

5 (2) DATE SPECIFIED.—With respect to an au-
6 thority described in paragraph (1), the date specified
7 in this paragraph is the later of—

8 (A) September 30, 2026;

9 (B) the date specified with respect to such
10 authority in the Agriculture Improvement Act
11 of 2018 (Public Law 115–334; 132 Stat. 4490)
12 or a provision of law amended by that Act
13 (Public Law 115–334; 132 Stat. 4490), includ-
14 ing any amendments made to such provisions
15 by—

16 (i) titles I and V of Public Law 119–
17 21 (139 Stat. 80, 137);

18 (ii) the Expanding Public Lands Out-
19 door Recreation Experiences Act (Public
20 Law 118–234; 138 Stat. 2836); and

21 (iii) any other provisions of law en-
22 acted after the Agriculture Improvement
23 Act of 2018 (Public Law 115–334; 132
24 Stat. 4490); and

1 (C) the date in effect with respect to such
2 authority pursuant to section 4101 of division
3 D of the American Relief Act, 2025 (Public
4 Law 118–158; 138 Stat. 1767)).

5 (b) DISCRETIONARY PROGRAMS.—Programs carried
6 out using the authorities described in subsection (a)(1)
7 that are funded by discretionary appropriations (as de-
8 fined in section 250(c) of the Balanced Budget and Emer-
9 gency Deficit Control Act of 1985 (2 U.S.C. 900(c))) shall
10 be subject to the availability of appropriations.

11 (c) COMMODITY PROGRAMS.—

12 (1) DAIRY FORWARD PRICING PROGRAM.—Sec-
13 tion 1502(e)(2) of the Food, Conservation, and En-
14 ergy Act of 2008 (7 U.S.C. 8772(e)(2)) is amended
15 by striking “2028” and inserting “2029”.

16 (2) SUSPENSION OF PERMANENT PRICE SUP-
17 PORT AUTHORITIES.—The provisions of law specified
18 in—

19 (A) subsections (a) and (b) of section 1602
20 of the Agricultural Act of 2014 (7 U.S.C.
21 9092)—

22 (i) shall not be applicable to the 2026
23 crops of covered commodities (as defined
24 in section 1111 of that Act (7 U.S.C.
25 9011)), cotton, and sugar; and

1 (ii) shall not be applicable to milk
2 through December 31, 2026; and

3 (B) section 1602(c) of that Act (7 U.S.C.
4 9092(c)) shall not be applicable to the crops of
5 wheat planted for harvest in calendar year
6 2026.

7 (d) OTHER PROGRAMS.—

8 (1) TRADE.—Section 302(h)(2) of the Bill
9 Emerson Humanitarian Trust Act (7 U.S.C. 1736f–
10 1(h)(2)) is amended by striking “September 30,
11 2025” and inserting “September 30, 2026”.

12 (2) GRAZINGLANDS RESEARCH LABORATORY.—
13 Section 7502 of the Food, Conservation, and Energy
14 Act of 2008 (Public Law 110–246; 122 Stat. 2019;
15 132 Stat. 4817; 138 Stat. 1769) is amended by
16 striking “2025” and inserting “2026”.

17 (3) ENERGY.—Section 9010(b) of the Farm Se-
18 curity and Rural Investment Act of 2002 (7 U.S.C.
19 8110(b)) is amended in paragraphs (1)(A) and
20 (2)(A) by striking “2025” each place it appears and
21 inserting “2026”.

22 (e) EXCEPTIONS.—

23 (1) COMMODITIES.—Subsection (a) does not
24 apply with respect to mandatory funding under sec-

1 tion 1614(c)(4) of the Agricultural Act of 2014 (7
2 U.S.C. 9097(c)(4)).

3 (2) CONSERVATION.—

4 (A) MANDATORY FUNDING.—Subsection
5 (a) does not apply with respect to mandatory
6 funding under the following provisions of law:

7 (i) Section 1240O(b)(3) of the Food
8 Security Act of 1985 (16 U.S.C. 3839bb–
9 2(b)(3)).

10 (ii) Subparagraphs (A) and (B) of
11 section 1241(a)(1) of the Food Security
12 Act of 1985 (16 U.S.C. 3841(a)(1)) for
13 fiscal years 2025 and 2026.

14 (B) LIMITATIONS.—Subsection (a) does
15 not apply with respect to limitations under the
16 following provisions of law:

17 (i) Section 1240G of the Food Secu-
18 rity Act of 1985 (16 U.S.C. 3839aa–7).

19 (ii) Section 1240L(f) of the Food Se-
20 curity Act of 1985 (16 U.S.C. 3839aa–
21 24(f)).

22 (3) RURAL DEVELOPMENT.—Subsection (a)
23 does not apply with respect to mandatory funding
24 under section 313B(e)(2) of the Rural Electrifica-
25 tion Act of 1936 (7 U.S.C. 940c–2(e)(2)).

1 (4) RESEARCH.—Subsection (a) does not apply
2 with respect to mandatory funding under the fol-
3 lowing provisions of law:

4 (A) Section 1446(b)(1) of the National Ag-
5 ricultural Research, Extension, and Teaching
6 Policy Act of 1977 (7 U.S.C. 3222a(b)(1)).

7 (B) Section 7601(g)(1)(A) of the Agricul-
8 tural Act of 2014 (7 U.S.C. 5939(g)(1)(A)).

9 (5) ENERGY.—Subsection (a) does not apply
10 with respect to mandatory funding under the fol-
11 lowing provisions of law:

12 (A) Section 9002(k)(1) of the Farm Secu-
13 rity and Rural Investment Act of 2002 (7
14 U.S.C. 8102(k)(1)).

15 (B) Section 9003(g)(1)(A) of the Farm Se-
16 curity and Rural Investment Act of 2002 (7
17 U.S.C. 8103(g)(1)(A)).

18 (6) HORTICULTURE.—Subsection (a) does not
19 apply with respect to mandatory funding under the
20 following provisions of law:

21 (A) Section 2123(c)(4) of the Organic
22 Foods Production Act of 1990 (7 U.S.C.
23 6522(c)(4)).

1 (B) Section 10109(c)(1) of the Agriculture
2 Improvement Act of 2018 (Public Law 115–
3 334).

4 (7) MISCELLANEOUS.—Subsection (a) does not
5 apply with respect to mandatory funding under sec-
6 tion 209(c) of the Agricultural Marketing Act of
7 1946 (7 U.S.C. 1627a(c)).

8 (f) REPORTS.—

9 (1) IN GENERAL.—Subject to paragraph (2),
10 any requirement under a provision of law described
11 in paragraph (1) of subsection (a) to submit a re-
12 port on a recurring basis, and the final report under
13 which was required to be submitted during fiscal
14 year 2025, shall continue, and the requirement shall
15 be carried out, on the same recurring basis, until the
16 later of the dates specified in paragraph (2) of that
17 subsection.

18 (2) APPROPRIATIONS REQUIRED.—If discre-
19 tionary appropriations (as defined in section 250(c)
20 of the Balanced Budget and Emergency Deficit Con-
21 trol Act of 1985 (2 U.S.C. 900(c))) are required to
22 carry out a reporting requirement described in para-
23 graph (1), the application of that paragraph to that
24 reporting requirement shall be subject to the avail-
25 ability of appropriations.

1 (g) EFFECTIVE DATE.—This section and the amend-
2 ments made by this section shall be applied and adminis-
3 tered as if this section and those amendments had been
4 enacted on September 30, 2025.

5 **DIVISION F—HEALTH**
6 **EXTENDERS**
7 **TITLE I—PUBLIC HEALTH**
8 **EXTENDERS**

9 **SEC. 6101. EXTENSION FOR COMMUNITY HEALTH CENTERS,**
10 **NATIONAL HEALTH SERVICE CORPS, AND**
11 **TEACHING HEALTH CENTERS THAT OPERATE**
12 **GME PROGRAMS.**

13 (a) EXTENSION FOR COMMUNITY HEALTH CEN-
14 TERS.—Section 10503(b)(1) of the Patient Protection and
15 Affordable Care Act (42 U.S.C. 254b–2(b)(1)) is amend-
16 ed—

17 (1) in subparagraph (I), by striking “and” at
18 the end; and

19 (2) by adding at the end the following:

20 “(K) \$1,423,890,411 for the period begin-
21 ning on October 1, 2025, and ending on Janu-
22 ary 30, 2026; and”.

23 (b) EXTENSION FOR THE NATIONAL HEALTH SERV-
24 ICE CORPS.—Section 10503(b)(2) of the Patient Protec-

tion and Affordable Care Act (42 U.S.C. 254b–2(b)(2))
is amended—

(1) in subparagraph (J), by striking “and” at
the end;

(2) in subparagraph (K), by striking the period
at the end and inserting “; and”; and

(3) by adding at the end the following:

“(L) \$115,315,068 for the period begin-
ning on October 1, 2025, and ending on Janu-
ary 30, 2026.”.

(c) TEACHING HEALTH CENTERS THAT OPERATE
GRADUATE MEDICAL EDUCATION PROGRAMS.—Section
340H(g)(1) of the Public Health Service Act (42 U.S.C.
256h(g)(1)) is amended—

(1) in subparagraph (E), by striking “and” at
the end;

(2) in subparagraph (F), by striking the period
at the end and inserting “; and”; and

(3) by adding at the end the following:

“(G) \$58,493,151 for the period beginning
on October 1, 2025, and ending on January 30,
2026.”.

(d) APPLICATION OF PROVISIONS.—Amounts appro-
priated pursuant to the amendments made by this section
shall be subject to the requirements contained in Public

1 Law 117–328 for funds for programs authorized under
2 sections 330 through 340 of the Public Health Service Act
3 (42 U.S.C. 254b et seq.).

4 (e) CONFORMING AMENDMENT.—Section 3014(h)(4)
5 of title 18, United States Code, is amended by striking
6 “and section 2101(d) of division B of the Full-Year Con-
7 tinuing Appropriations and Extensions Act, 2025” and in-
8 serting “section 2101(d) of division B of the Full-Year
9 Continuing Appropriations and Extensions Act, 2025, and
10 section 6101(d) of the Continuing Appropriations, Agri-
11 culture, Legislative Branch, Military Construction and
12 Veterans Affairs, and Extensions Act, 2026”.

13 **SEC. 6102. EXTENSION OF SPECIAL DIABETES PROGRAMS.**

14 (a) EXTENSION OF SPECIAL DIABETES PROGRAMS
15 FOR TYPE I DIABETES.—Section 330B(b)(2) of the Pub-
16 lic Health Service Act (42 U.S.C. 254c–2(b)(2)) is amend-
17 ed—

18 (1) in subparagraph (F), by striking “and” at
19 the end;

20 (2) in subparagraph (G), by striking the period
21 at the end and inserting “; and”; and

22 (3) by adding at the end the following:

23 “(H) \$53,145,205 for the period beginning
24 on October 1, 2025, and ending on January 30,
25 2026, to remain available until expended.”.

1 (b) EXTENDING FUNDING FOR SPECIAL DIABETES
2 PROGRAMS FOR INDIANS.—Section 330C(c)(2) of the
3 Public Health Service Act (42 U.S.C. 254c–3(c)(2)) is
4 amended—

5 (1) in subparagraph (F), by striking “and” at
6 the end;

7 (2) in subparagraph (G), by striking the period
8 at the end and inserting “; and”; and

9 (3) by adding at the end the following:

10 “(H) \$53,145,205 for the period beginning
11 on October 1, 2025, and ending on January 30,
12 2026, to remain available until expended.”.

13 **SEC. 6103. NATIONAL HEALTH SECURITY EXTENSIONS.**

14 (a) Section 319(e)(8) of the Public Health Service
15 Act (42 U.S.C. 247d(e)(8)) is amended by striking “Sep-
16 tember 30, 2025” and inserting “January 30, 2026”.

17 (b) Section 319L(e)(1)(D) of the Public Health Serv-
18 ice Act (42 U.S.C. 247d–7e(e)(1)(D)) is amended by strik-
19 ing “September 30, 2025” and inserting “January 30,
20 2026”.

21 (c) Section 319L–1(b) of the Public Health Service
22 Act (42 U.S.C. 247d–7f(b)) is amended by striking “Sep-
23 tember 30, 2025” and inserting “January 30, 2026”.

1 (d)(1) Section 2811A(g) of the Public Health Service
2 Act (42 U.S.C. 300hh–10b(g)) is amended by striking
3 “September 30, 2025” and inserting “January 30, 2026”.

4 (2) Section 2811B(g)(1) of the Public Health Service
5 Act (42 U.S.C. 300hh–10c(g)(1)) is amended by striking
6 “September 30, 2025” and inserting “January 30, 2026”.

7 (3) Section 2811C(g)(1) of the Public Health Service
8 Act (42 U.S.C. 300hh–10d(g)(1)) is amended by striking
9 “September 30, 2025” and inserting “January 30, 2026”.

10 (e) Section 2812(c)(4)(B) of the Public Health Serv-
11 ice Act (42 U.S.C. 300hh–11(c)(4)(B)) is amended by
12 striking “September 30, 2025” and inserting “January
13 30, 2026”.

14 **TITLE II—MEDICARE**

15 **SEC. 6201. EXTENSION OF INCREASED INPATIENT HOS-** 16 **PITAL PAYMENT ADJUSTMENT FOR CERTAIN** 17 **LOW-VOLUME HOSPITALS.**

18 (a) IN GENERAL.—Section 1886(d)(12) of the Social
19 Security Act (42 U.S.C. 1395ww(d)(12)) is amended—

20 (1) in subparagraph (B), by striking “in fiscal
21 year 2026” and inserting “during the portion of fis-
22 cal year 2026 beginning on January 31, 2026, and
23 ending on September 30, 2026, and in fiscal year
24 2027”;

25 (2) in subparagraph (C)(i)—

1 (A) in the matter preceding subclause

2 (I)—

3 (i) by inserting “or portion of a fiscal
4 year” after “for a fiscal year”; and

5 (ii) by inserting “and the portion of
6 fiscal year 2026 beginning on October 1,
7 2025, and ending on January 30, 2026”
8 after “through 2025”;

9 (B) in subclause (III), by inserting “and
10 the portion of fiscal year 2026 beginning on Oc-
11 tober 1, 2025, and ending on January 30,
12 2026” after “through 2025”; and

13 (C) in subclause (IV), by striking “fiscal
14 year 2026” and inserting “the portion of fiscal
15 year 2026 beginning on January 31, 2026, and
16 ending on September 30, 2026, and fiscal year
17 2027”; and

18 (3) in subparagraph (D)—

19 (A) in the matter preceding clause (i), by
20 inserting “or during the portion of fiscal year
21 2026 beginning on October 1, 2025, and ending
22 on January 30, 2026” after “through 2025”;
23 and

24 (B) in clause (ii), by inserting “and the
25 portion of fiscal year 2026 beginning on Octo-

ber 1, 2025, and ending on January 30, 2026”
after “through 2025”.

(b) IMPLEMENTATION.—Notwithstanding any other
provision of law, the Secretary of Health and Human
Services may implement the amendments made by this
section by program instruction or otherwise.

**SEC. 6202. EXTENSION OF THE MEDICARE-DEPENDENT
HOSPITAL (MDH) PROGRAM.**

(a) IN GENERAL.—Section 1886(d)(5)(G) of the So-
cial Security Act (42 U.S.C. 1395ww(d)(5)(G)) is amend-
ed—

(1) in clause (i), by striking “October 1, 2025”
and inserting “January 31, 2026”; and

(2) in clause (ii)(II), by striking “October 1,
2025” and inserting “January 31, 2026”.

(b) CONFORMING AMENDMENTS.—

(1) IN GENERAL.—Section 1886(b)(3)(D) of
the Social Security Act (42 U.S.C.
1395ww(b)(3)(D)) is amended—

(A) in the matter preceding clause (i), by
striking “October 1, 2025” and inserting “Jan-
uary 31, 2026”; and

(B) in clause (iv), by inserting “and the
portion of fiscal year 2026 beginning on Octo-

1 ber 1, 2025, and ending on January 30, 2026”
2 after “through fiscal year 2025”.

3 (2) PERMITTING HOSPITALS TO DECLINE RE-
4 CLASSIFICATION.—Section 13501(e)(2) of the Omni-
5 bus Budget Reconciliation Act of 1993 (42 U.S.C.
6 1395ww note) is amended by inserting “, or the por-
7 tion of fiscal year 2026 beginning on October 1,
8 2025, and ending on January 30, 2026” after
9 “through fiscal year 2025”.

10 **SEC. 6203. EXTENSION OF FUNDING FOR QUALITY MEAS-**
11 **URE ENDORSEMENT, INPUT, AND SELECTION.**

12 Section 1890(d)(2) of the Social Security Act (42
13 U.S.C. 1395aaa(d)(2)) is amended—

14 (1) in the first sentence—

15 (A) by striking “and \$14,030,000” and in-
16 serting “\$14,030,000”; and

17 (B) by inserting the following before the
18 period at the end: “, and \$13,300,000 for fiscal
19 year 2026”; and

20 (2) in the third sentence, by striking “and 2024
21 and the period beginning on October 1, 2024, and
22 ending on September 30, 2025,” and inserting
23 “2024, 2025, and 2026”.

1 **SEC. 6204. EXTENDING ACUTE HOSPITAL CARE AT HOME**
2 **WAIVER AUTHORITIES.**

3 Section 1866G(a)(1) of the Social Security Act (42
4 U.S.C. 1395cc–7(a)(1)) is amended by striking “Sep-
5 tember 30, 2025” and inserting “January 30, 2026”.

6 **SEC. 6205. EXTENSION OF FUNDING FOR MEDICARE HOS-**
7 **PICE SURVEYS.**

8 Section 3(a)(2) of the IMPACT Act of 2014 (Public
9 Law 113–185) is amended—

10 (1) in subparagraph (A), by striking “and” at
11 the end;

12 (2) in subparagraph (B), by striking the period
13 at the end and inserting “; and”; and

14 (3) by adding at the end the following new sub-
15 paragraph:

16 “(C) \$2,000,000 for the period beginning
17 on October 1, 2025, and ending on January 30,
18 2026.”.

19 **SEC. 6206. EXTENSION OF ADD-ON PAYMENTS FOR AMBU-**
20 **LANCE SERVICES.**

21 Section 1834(l) of the Social Security Act (42 U.S.C.
22 1395m(l)) is amended—

23 (1) in paragraph (12)(A), by striking “October
24 1, 2025” and inserting “January 31, 2026”; and

1 (2) in paragraph (13), by striking “October 1,
2 2025” each place it appears and inserting “January
3 31, 2026” in each such place.

4 **SEC. 6207. EXTENSION OF THE WORK GEOGRAPHIC INDEX**
5 **FLOOR.**

6 Section 1848(e)(1)(E) of the Social Security Act (42
7 U.S.C. 1395w-4(e)(1)(E)) is amended by striking “Octo-
8 ber 1, 2025” and inserting “January 31, 2026”.

9 **SEC. 6208. EXTENSION OF CERTAIN TELEHEALTH FLEXI-**
10 **BILITIES.**

11 (a) REMOVING GEOGRAPHIC REQUIREMENTS AND
12 EXPANDING ORIGINATING SITES FOR TELEHEALTH
13 SERVICES.—Section 1834(m) of the Social Security Act
14 (42 U.S.C. 1395m(m)) is amended—

15 (1) in paragraph (2)(B)(iii), by striking “end-
16 ing September 30, 2025” and inserting “ending
17 January 30, 2026”; and

18 (2) in paragraph (4)(C)(iii), by striking “ending
19 on September 30, 2025” and inserting “ending on
20 January 30, 2026”.

21 (b) EXPANDING PRACTITIONERS ELIGIBLE TO FUR-
22 NISH TELEHEALTH SERVICES.—Section 1834(m)(4)(E)
23 of the Social Security Act (42 U.S.C. 1395m(m)(4)(E))
24 is amended by striking “ending on September 30, 2025”
25 and inserting “ending on January 30, 2026”.

1 (c) EXTENDING TELEHEALTH SERVICES FOR FED-
2 ERALLY QUALIFIED HEALTH CENTERS AND RURAL
3 HEALTH CLINICS.—Section 1834(m)(8)(A) of the Social
4 Security Act (42 U.S.C. 1395m(m)(8)(A)) is amended by
5 striking “ending on September 30, 2025” and inserting
6 “ending on January 30, 2026”.

7 (d) DELAYING THE IN-PERSON REQUIREMENTS
8 UNDER MEDICARE FOR MENTAL HEALTH SERVICES
9 FURNISHED THROUGH TELEHEALTH AND TELE-
10 COMMUNICATIONS TECHNOLOGY.—

11 (1) DELAY IN REQUIREMENTS FOR MENTAL
12 HEALTH SERVICES FURNISHED THROUGH TELE-
13 HEALTH.—Section 1834(m)(7)(B)(i) of the Social
14 Security Act (42 U.S.C. 1395m(m)(7)(B)(i)) is
15 amended, in the matter preceding subclause (I), by
16 striking “on or after October 1, 2025” and inserting
17 “on or after January 31, 2026”.

18 (2) MENTAL HEALTH VISITS FURNISHED BY
19 RURAL HEALTH CLINICS.—Section 1834(y)(2) of the
20 Social Security Act (42 U.S.C. 1395m(y)(2)) is
21 amended by striking “October 1, 2025” and insert-
22 ing “January 31, 2026”.

23 (3) MENTAL HEALTH VISITS FURNISHED BY
24 FEDERALLY QUALIFIED HEALTH CENTERS.—Section
25 1834(o)(4)(B) of the Social Security Act (42 U.S.C.

1 1395m(o)(4)(B)) is amended by striking “October 1,
2 2025” and inserting “January 31, 2026”.

3 (e) ALLOWING FOR THE FURNISHING OF AUDIO-
4 ONLY TELEHEALTH SERVICES.—Section 1834(m)(9) of
5 the Social Security Act (42 U.S.C. 1395m(m)(9)) is
6 amended by striking “ending on September 30, 2025” and
7 inserting “ending on January 30, 2026”.

8 (f) EXTENDING USE OF TELEHEALTH TO CONDUCT
9 FACE-TO-FACE ENCOUNTER PRIOR TO RECERTIFICATION
10 OF ELIGIBILITY FOR HOSPICE CARE.—Section
11 1814(a)(7)(D)(i)(II) of the Social Security Act (42 U.S.C.
12 1395f(a)(7)(D)(i)(II)) is amended by striking “ending on
13 September 30, 2025” and inserting “ending on January
14 30, 2026”.

15 (g) PROGRAM INSTRUCTION AUTHORITY.—The Sec-
16 retary of Health and Human Services may implement the
17 amendments made by this section through program in-
18 struction or otherwise.

19 **SEC. 6209. REVISING PHASE-IN OF MEDICARE CLINICAL**
20 **LABORATORY TEST PAYMENT CHANGES.**

21 (a) REVISED PHASE-IN OF REDUCTIONS FROM PRI-
22 VATE PAYOR RATE IMPLEMENTATION.—Section
23 1834A(b)(3)(B) of the Social Security Act (42 U.S.C.
24 1395m–1(b)(3)(B)) is amended—

1 (1) in clause (ii), by inserting “and for the pe-
2 riod beginning on January 1, 2026, and ending on
3 January 30, 2026” after “2025”; and

4 (2) in clause (iii), by striking “for each of 2026
5 through 2028” and inserting “for the period begin-
6 ning on January 31, 2026, and ending on December
7 31, 2026, and for each of 2027 and 2028”.

8 (b) REVISED REPORTING PERIOD FOR REPORTING
9 OF PRIVATE SECTOR PAYMENT RATES FOR ESTABLISH-
10 MENT OF MEDICARE PAYMENT RATES.—Section
11 1834A(a)(1)(B) of the Social Security Act (42 U.S.C.
12 1395m–1(a)(1)(B)) is amended—

13 (1) in clause (i), by striking “December 31,
14 2025” and inserting “January 31, 2026”; and

15 (2) in clause (ii), by striking “January 1, 2026,
16 and ending March 31, 2026” and inserting “Feb-
17 ruary 1, 2026, and ending April 30, 2026”.

18 **SEC. 6210. EXTENSION OF FUNDING OUTREACH AND AS-**
19 **SISTANCE FOR LOW-INCOME PROGRAMS.**

20 (a) STATE HEALTH INSURANCE ASSISTANCE PRO-
21 GRAMS.—Subsection (a)(1)(B) of section 119 of the Medi-
22 care Improvements for Patients and Providers Act of 2008
23 (42 U.S.C. 1395b–3 note) is amended—

24 (1) in clause (xiii), by striking “and” at the
25 end;

1 (2) in clause (xiv), by striking the period at the
2 end and inserting “; and”; and

3 (3) by inserting after clause (xiv) the following
4 new clause:

5 “(xv) for the period beginning on Oc-
6 tober 1, 2025, and ending on January 30,
7 2026, \$5,013,699.”.

8 (b) AREA AGENCIES ON AGING.—Subsection
9 (b)(1)(B) of such section 119 is amended—

10 (1) in clause (xiii), by striking “and” at the
11 end;

12 (2) in clause (xiv), by striking the period at the
13 end and inserting “; and”; and

14 (3) by inserting after clause (xiv) the following
15 new clause:

16 “(xv) for the period beginning on Oc-
17 tober 1, 2025, and ending on January 30,
18 2026, \$5,013,699.”.

19 (c) AGING AND DISABILITY RESOURCE CENTERS.—
20 Subsection (c)(1)(B) of such section 119 is amended—

21 (1) in clause (xiii), by striking “and” at the
22 end;

23 (2) in clause (xiv), by striking the period at the
24 end and inserting “; and”; and

1 (3) by inserting after clause (xiv) the following
2 new clause:

3 “(xv) for the period beginning on Oc-
4 tober 1, 2025, and ending on January 30,
5 2026, \$1,671,233.”.

6 (d) COORDINATION OF EFFORTS TO INFORM OLDER
7 AMERICANS ABOUT BENEFITS AVAILABLE UNDER FED-
8 ERAL AND STATE PROGRAMS.—Subsection (d)(2) of such
9 section 119 is amended—

10 (1) in clause (xiii), by striking “and” at the
11 end;

12 (2) in clause (xiv), by striking the period at the
13 end and inserting “; and”; and

14 (3) by inserting after clause (xiv) the following
15 new clause:

16 “(xv) for the period beginning on October
17 1, 2025, and ending on January 30, 2026,
18 \$5,013,699.”.

19 **SEC. 6211. EXTENSION OF TEMPORARY INCLUSION OF AU-**
20 **THORIZED ORAL ANTIVIRAL DRUGS AS COV-**
21 **ERED PART D DRUGS.**

22 Section 1860D–2(e)(1)(C) of the Social Security Act
23 (42 U.S.C. 1395w–102(e)(1)(C)) is amended by striking
24 “September 30, 2025” and inserting “January 30, 2026”.

1 **SEC. 6212. MEDICARE IMPROVEMENT FUND.**

2 Section 1898(b)(1) of the Social Security Act (42
3 U.S.C. 1395iii(b)(1)) is amended—

4 (1) by striking “fiscal year 2026” and inserting
5 “fiscal year 2027”; and

6 (2) by striking “\$1,804,000,000” and inserting
7 “\$1,403,000,000”.

8 **SEC. 6213. MEDICARE SEQUESTRATION.**

9 Section 251A(6)(D) of the Balanced Budget and
10 Emergency Deficit Control Act of 1985 (2 U.S.C.
11 901a(6)(D)) is amended—

12 (1) in clause (i), by striking “10 months” and
13 inserting “11 months”; and

14 (2) in clause (ii), by striking “2 months” and
15 inserting “1 month”.

16 **TITLE III—HUMAN SERVICES**

17 **SEC. 6301. SEXUAL RISK AVOIDANCE EDUCATION EXTEN-**
18 **SION.**

19 Section 510 of the Social Security Act (42 U.S.C.
20 710) is amended—

21 (1) in subsection (a)—

22 (A) in paragraph (1)—

23 (i) by striking “2023, for the period
24 beginning on October 1, 2023, and ending
25 on November 17, 2023, for the period be-
26 ginning on November 18, 2023, and end-

ing on January 19, 2024, for the period
beginning on January 20, 2024, and end-
ing on March 8, 2024, for the period be-
ginning on March 9, 2024, and ending on
September 30, 2024, and for fiscal year
2025” and inserting “2025, and for the
period beginning on October 1, 2025, and
ending on January 30, 2026”; and

(ii) by striking “fiscal year 2024” and
inserting “fiscal year 2026”; and

(B) in paragraph (2)—

(i) in subparagraph (A)—

(I) by striking “through 2023”
and inserting “through 2025”;

(II) by striking “fiscal year 2024
or 2025” and inserting “fiscal year
2026”; and

(III) by inserting “(or, with re-
spect to the applicable period, for fis-
cal year 2026)” after “an application
for the fiscal year”; and

(ii) in subparagraph (B)(i), by strik-
ing “2024 or 2025” and inserting “2026”;
and

1 (2) in subsection (f)(1) by striking “2023, for
2 the period beginning on October 1, 2023, and ending
3 on November 17, 2023, an amount equal to the pro
4 rata portion of the amount appropriated for the cor-
5 responding period for fiscal year 2023, for the pe-
6 riod beginning on November 18, 2023, and ending
7 on January 19, 2024, an amount equal to the pro
8 rata portion of the amount appropriated for the cor-
9 responding period for fiscal year 2023, for the pe-
10 riod beginning on January 20, 2024, and ending on
11 March 8, 2024, an amount equal to the pro rata
12 portion of the amount appropriated for the period at
13 the end of the corresponding sentence for fiscal year
14 2023, for the period beginning on March 9, 2024,
15 and ending on September 30, 2024, an amount
16 equal to the pro rata portion of the amount appro-
17 priated for the corresponding period for fiscal year
18 2023, and for for fiscal year 2025, an amount equal
19 to the amount appropriated for fiscal year 2024”
20 and inserting “2025, and for the period beginning
21 on October 1, 2025, and ending on January 30,
22 2026, an amount equal to the pro rata portion of
23 the amount appropriated for the corresponding pe-
24 riod for fiscal year 2025”.

1 **SEC. 6302. PERSONAL RESPONSIBILITY EDUCATION EXTEN-**
2 **SION.**

3 Section 513 of the Social Security Act (42 U.S.C.
4 713) is amended—

5 (1) in subsection (a)(1)—

6 (A) in subparagraph (A), in the matter
7 preceding clause (i), by striking “2023, for the
8 period beginning on October 1, 2023, and end-
9 ing on November 17, 2023, for the period be-
10 ginning on November 18, 2023, and ending on
11 January 19, 2024, for the period beginning on
12 January 20, 2024, and ending on March 8,
13 2024, for the period beginning on March 9,
14 2024, and ending on September 30, 2024, and
15 for fiscal year 2025” and inserting “2025, and
16 for the period beginning on October 1, 2025,
17 and ending on January 30, 2026”; and

18 (B) in subparagraph (B)(i), by striking
19 “the period beginning on October 1, 2023, and
20 ending on November 17, 2023, for the period
21 beginning on November 18, 2023, and ending
22 on January 19, 2024, for the period beginning
23 on January 20, 2024, and ending on March 8,
24 2024, for the period beginning on March 9,
25 2024, and ending on September 30, 2024, and
26 for fiscal year 2025” and inserting “fiscal years

1 2024 and 2025, and for the period beginning
2 on October 1, 2025, and ending on January 30,
3 2026”;

4 (2) in subsection (c)(3), by striking “2024 or
5 2025” and inserting “2026”; and

6 (3) in subsection (f), by striking “2023, for the
7 period beginning on October 1, 2023, and ending on
8 November 17, 2023, an amount equal to the pro
9 rata portion of the amount appropriated for the cor-
10 responding period for fiscal year 2023, for the pe-
11 riod beginning on November 18, 2023, and ending
12 on January 19, 2024, an amount equal to the pro
13 rata portion of the amount appropriated for the cor-
14 responding period for fiscal year 2023, for the pe-
15 riod beginning on January 20, 2024, and ending on
16 March 8, 2024, an amount equal to the pro rata
17 portion of the amount appropriated for the cor-
18 responding period for fiscal year 2023, for the pe-
19 riod beginning on March 9, 2024, and ending on
20 September 30, 2024, an amount equal to the pro
21 rata portion of the amount appropriated for the cor-
22 responding period for fiscal year 2023, and for fiscal
23 year 2025, an amount equal to the amount appro-
24 priated for fiscal year 2024 for fiscal year 2024”
25 and inserting “2025, and for the period beginning

1 on October 1, 2025, and ending on January 30,
2 2026, an amount equal to the pro rata portion of
3 the amount appropriated for the corresponding pe-
4 riod for fiscal year 2025”.

5 **SEC. 6303. EXTENSION OF FUNDING FOR FAMILY-TO-FAM-**
6 **ILY HEALTH INFORMATION CENTERS.**

7 Section 501(c)(1)(A) of the Social Security Act (42
8 U.S.C. 701(c)(1)(A)) is amended—

9 (1) in clause (vii), by striking “and” at the end;
10 (2) in clause (viii), by adding “; and” at the
11 end; and

12 (3) by adding at the end the following new
13 clause:

14 “(ix) for the period beginning on October 1,
15 2025, and ending on January 30, 2026, an amount
16 equal to the pro rata portion of the amount appro-
17 priated for fiscal year 2025.”.

18 **TITLE IV—MEDICAID**

19 **SEC. 6401. MODIFYING CERTAIN DISPROPORTIONATE**
20 **SHARE HOSPITAL ALLOTMENTS.**

21 (a) EXTENDING TENNESSEE DSH ALLOTMENTS.—

22 Section 1923(f)(6)(A)(vi) of the Social Security Act (42
23 U.S.C. 1396r–4(f)(6)(A)(vi)) is amended—

24 (1) in the heading, by inserting “AND A POR-
25 TION OF FISCAL YEAR 2026” after “2025”; and

1 (2) by inserting “, and the DSH allotment for
2 Tennessee for the portion of fiscal year 2026 begin-
3 ning October 1, 2025, and ending January 30,
4 2026, shall be \$17,748,493, which may be claimed
5 as fiscal year 2026 uncompensated care costs” be-
6 fore the period.

7 (b) DELAYING DSH ALLOTMENT REDUCTIONS.—
8 Section 1923(f) of the Social Security Act (42 U.S.C.
9 1396r-4(f)) is amended—

10 (1) in paragraph (7)(A)—

11 (A) in clause (i)—

12 (i) in the matter preceding subclause
13 (I), by striking “For each of fiscal years
14 2026 through 2028” and inserting “For
15 the period beginning January 31, 2026,
16 and ending September 30, 2026, and for
17 each of fiscal years 2027 and 2028”;

18 (ii) in subclause (I), by inserting “or
19 period” after “the fiscal year”; and

20 (iii) in subclause (II), by inserting “or
21 period” after “in the fiscal year”; and

22 (B) in clause (ii), by striking “for each of
23 fiscal years 2026 through 2028” and inserting
24 “for the period beginning January 31, 2026,

1 and ending September 30, 2026, and for each
2 of fiscal years 2027 and 2028”; and
3 (2) in paragraph (8), by striking “2027” and
4 inserting “2028”.

5 **TITLE V—FOOD AND DRUG**
6 **ADMINISTRATION**

7 **SEC. 6501. SHORT TITLE.**

8 This title may be cited as the “Over-the-Counter
9 Monograph Drug User Fee Amendments”.

10 **SEC. 6502. FINDING.**

11 Congress finds that the fees authorized by the
12 amendments made in this title will be dedicated to over-
13 the-counter (OTC) monograph drug activities, as set forth
14 in the goals identified for purposes of part 10 of sub-
15 chapter C of chapter VII of the Federal Food, Drug, and
16 Cosmetic Act (21 U.S.C. 379j–71 et seq.), in the letters
17 from the Secretary of Health and Human Services to the
18 Chairman of the Committee on Energy and Commerce of
19 the House of Representatives and the Chairman of the
20 Committee on Health, Education, Labor, and Pensions of
21 the Senate, as set forth in the Congressional Record.

22 **SEC. 6503. DEFINITIONS.**

23 Section 744L(9)(A) of the Federal Food, Drug, and
24 Cosmetic Act (21 U.S.C. 379j–71(9)(A)) is amended—

1 (1) in clause (v), by striking “; or” and insert-
2 ing a semicolon;

3 (2) in clause (vi)—

4 (A) by striking “addition” and inserting
5 “the addition”; and

6 (B) by striking the period and inserting “;
7 or”; and

8 (3) by adding at the end the following:

9 “(vii) the addition or modification of a
10 testing procedure applicable to one or more
11 OTC monograph drugs, provided that such ad-
12 ditional or modified testing procedure reflects a
13 voluntary consensus standard with respect to
14 pharmaceutical quality that is—

15 “(I) established by a national or inter-
16 national standards development organiza-
17 tion; and

18 “(II) recognized by the Secretary
19 through a process described in guidance
20 for industry, initially published in July
21 2023, or any successor guidance, publicly
22 available on the website of the Food and
23 Drug Administration, which addresses vol-
24 untary consensus standards for pharma-
25 ceutical quality.”.

1 **SEC. 6504. AUTHORITY TO ASSESS AND USE OTC MONO-**
2 **GRAPH FEES.**

3 (a) TYPES OF FEES.—Section 744M(a)(1) of the
4 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
5 72(a)(1)) is amended—

6 (1) in subparagraph (A)—

7 (A) by striking “on December 31 of the
8 fiscal year or at any time during the preceding
9 12-month period” and inserting “at any time
10 during the applicable period specified in clause
11 (ii) for a fiscal year”;

12 (B) by striking “Each person” and insert-
13 ing the following:

14 “(i) ASSESSMENT OF FEES.—Each
15 person”; and

16 (C) by adding at the end the following:

17 “(ii) APPLICABLE PERIOD.—For pur-
18 poses of clause (i), the applicable period
19 is—

20 “(I) for fiscal year 2026, the 12-
21 month period ending on December 31,
22 2025;

23 “(II) for fiscal year 2027, the 9-
24 month period ending on September
25 30, 2026; and

1 “(III) for fiscal year 2028 and
2 each subsequent fiscal year, the 12-
3 month period ending on September 30
4 of the preceding fiscal year.”;

5 (2) in subparagraph (B)(i), by amending sub-
6 clause (I) to read as follows:

7 “(I) has ceased all activities re-
8 lated to OTC monograph drugs prior
9 to—

10 “(aa) for purposes of fiscal
11 year 2026, January 1, 2025;

12 “(bb) for purposes of fiscal
13 year 2027, January 1, 2026; and

14 “(cc) for purposes of fiscal
15 year 2028 and each subsequent
16 fiscal year, October 1 of the pre-
17 ceding fiscal year; and”;

18 (3) by amending subparagraph (D) to read as
19 follows:

20 “(D) DUE DATE.—

21 “(i) FISCAL YEAR 2026.—For fiscal
22 year 2026, the facility fees required under
23 subparagraph (A) shall be due on the later
24 of—

1 “(I) the first business day of
2 June of such year; or

3 “(II) the first business day after
4 the enactment of an appropriations
5 Act providing for the collection and
6 obligation of fees under this section
7 for such year.

8 “(ii) FISCAL YEAR 2027.—For fiscal
9 year 2027, the facility fees required under
10 subparagraph (A) shall be due—

11 “(I) in a first installment rep-
12 resenting 50 percent of such fee, on
13 the later of—

14 “(aa) October 1, 2026; or

15 “(bb) the first business day
16 after the enactment of an appro-
17 priations Act providing for the
18 collection and obligation of fees
19 under this section for such year;
20 and

21 “(II) in a second installment rep-
22 resenting the remaining 50 percent of
23 such fee, on—

24 “(aa) February 1, 2027; or

1 “(bb) if an appropriations
2 Act described in subclause
3 (I)(bb) is not in effect on Feb-
4 ruary 1, 2027, the first business
5 day after enactment of such an
6 appropriations Act.

7 “(iii) SUBSEQUENT FISCAL YEARS.—
8 For fiscal year 2028 and each subsequent
9 fiscal year, the facility fees required under
10 subparagraph (A) shall be due on the later
11 of—

12 “(I) the first business day on or
13 after October 1 of the fiscal year; or

14 “(II) the first business day after
15 the date of enactment of an appro-
16 priations Act providing for the collec-
17 tion and obligation of fees under this
18 section for the fiscal year.”.

19 (b) FEE REVENUE AMOUNTS.—Section 744M(b) of
20 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
21 379j–72(b)) is amended to read as follows:

22 “(b) FEE REVENUE AMOUNTS.—

23 “(1) IN GENERAL.—For each of the fiscal years
24 2026 through 2030, fees under subsection (a)(1)

1 shall be established to generate a total facility fee
2 revenue amount equal to the sum of—

3 “(A) the annual base revenue for the fiscal
4 year (as determined under paragraph (2));

5 “(B) the dollar amount equal to the infla-
6 tion adjustment for the fiscal year (as deter-
7 mined under subsection (c)(1));

8 “(C) the dollar amount equal to the oper-
9 ating reserve adjustment for the fiscal year, if
10 applicable (as determined under subsection
11 (c)(2));

12 “(D) additional direct cost adjustments (as
13 determined under subsection (c)(3));

14 “(E) an additional dollar amount equal
15 to—

16 “(i) \$2,373,000 for fiscal year 2026;

17 “(ii) \$1,233,000 for fiscal year 2027;

18 and

19 “(iii) \$854,000 for fiscal year 2028;

20 and

21 “(F) in the case of a fiscal year for which
22 the Secretary applies the one-time facility fee
23 workload adjustment under subsection (c)(4),
24 the dollar amount equal to such adjustment.

1 “(2) ANNUAL BASE REVENUE.—For purposes
2 of paragraph (1), the dollar amount of the annual
3 base revenue for a fiscal year shall be—

4 “(A) for fiscal year 2026, the dollar
5 amount of the total revenue amount established
6 for fiscal year 2025 under this subsection as in
7 effect on the day before the date of enactment
8 of the Over-the-Counter Monograph Drug User
9 Fee Amendments, not including any adjust-
10 ments made for such fiscal year 2025 under
11 subsection (c)(2), as so in effect; and

12 “(B) for fiscal years 2027 through 2030,
13 the dollar amount of the total revenue amount
14 established under this subsection for the pre-
15 vious fiscal year, not including any adjustments
16 made for such previous fiscal year under sub-
17 section (c)(2) or (c)(3).”.

18 (c) ADJUSTMENTS; ANNUAL FEE SETTING.—Section
19 744M(c) of the Federal Food, Drug, and Cosmetic Act
20 (21 U.S.C. 379j–72(c)) is amended—

21 (1) in paragraph (1)—

22 (A) in subparagraph (A), in the matter
23 preceding clause (i)—

24 (i) by striking “subsection (b)(2)(B)”
25 and inserting “subsection (b)(1)(B)”; and

1 (ii) by striking “fiscal year 2022 and
2 each subsequent fiscal year” and inserting
3 “each fiscal year”;

4 (B) in subparagraph (B), by striking “fis-
5 cal year 2022” and all that follows through the
6 period at the end and inserting the following:
7 “a fiscal year shall be equal to the product of—

8 “(i) for fiscal year 2026—

9 “(I) the fee for fiscal year 2025
10 under subsection (a)(2); and

11 “(II) the inflation adjustment
12 percentage under subparagraph (C);
13 and

14 “(ii) for each of fiscal years 2027
15 through 2030—

16 “(I) the applicable fee under sub-
17 section (a)(2) for the preceding fiscal
18 year; and

19 “(II) the inflation adjustment
20 percentage under subparagraph (C).”;
21 and

22 (C) in subparagraph (C)—

23 (i) in the matter preceding clause (i),
24 by inserting “the sum of” after “is equal
25 to”;

1 (ii) by striking clause (i);

2 (iii) by redesignating subclauses (I)
3 and (II) of clause (ii) as clauses (i) and
4 (ii), respectively, and adjusting the mar-
5 gins accordingly;

6 (iv) by striking “(ii) for each of fiscal
7 years 2024 and 2025, the sum of—”; and

8 (v) in clause (ii), as so redesignated,
9 by striking “Washington-Baltimore, DC–
10 MD–VA–WV” and inserting “Washington–
11 Arlington–Alexandria–DC–VA–MD–WV”;

12 (2) in paragraph (2)—

13 (A) in subparagraph (A)—

14 (i) by striking “fiscal year 2021 and
15 subsequent fiscal years” and inserting
16 “each fiscal year”;

17 (ii) by striking “subsections (b)(1)(B)
18 and (b)(2)(C)” and inserting “subsection
19 (b)(1)(C)”; and

20 (iii) by striking “the number of weeks
21 specified in subparagraph (B)” and insert-
22 ing “10 weeks”;

23 (B) by striking subparagraph (B);

1 (C) by redesignating subparagraphs (C)
2 and (D) as subparagraphs (B) and (C), respec-
3 tively; and

4 (D) in subparagraph (C), as so redesign-
5 nated, by striking “paragraph (4) establishing”
6 and inserting “paragraph (5) publishing”;
7 (3) in paragraph (3)—

8 (A) in the matter preceding subparagraph
9 (A), by striking “subsection (b)(2)(D)” and in-
10 sserting “subsection (b)(1)(D)”;

11 (B) by striking subparagraphs (A) through
12 (E) and inserting the following:

13 “(A) \$135,000 for fiscal year 2026;

14 “(B) \$300,000 for fiscal year 2027;

15 “(C) \$55,000 for fiscal year 2028;

16 “(D) \$30,000 for fiscal year 2029; and

17 “(E) \$0 for fiscal year 2030.”; and

18 (4) by striking paragraph (4) and inserting the
19 following:

20 “(4) ONE-TIME FACILITY FEE WORKLOAD AD-
21 JUSTMENT.—

22 “(A) IN GENERAL.—In addition to the ad-
23 justments under paragraphs (1), (2), and (3),
24 the Secretary may further increase the fee reve-
25 nues and fees through a one-time adjustment

1 made for fiscal year 2028, 2029, or 2030, in
2 accordance with this paragraph.

3 “(B) ADJUSTMENT DESCRIBED.—

4 “(i) CONDITIONS FOR ADJUST-
5 MENT.—An adjustment under this para-
6 graph may be made for a fiscal year only
7 if—

8 “(I) an adjustment under this
9 paragraph had not been made for any
10 prior fiscal year;

11 “(II) the average number of OTC
12 monograph drug facilities subject to a
13 facility fee under subsection (a)(1)
14 over the period of the preceding 3 fis-
15 cal years exceeds 1,625; and

16 “(III) with respect to facilities
17 described in subclause (II), the aver-
18 age number of such facilities (ex-
19 pressed as a percentage) that ap-
20 peared on the arrears lists pursuant
21 to subsection (e)(1)(A)(i) over the pe-
22 riod of the preceding 3 fiscal years is
23 less than 30 percent.

1 “(ii) AMOUNT OF ADJUSTMENT.—An
2 adjustment under this paragraph for a fis-
3 cal year shall equal the product of—

4 “(I) the total facility revenue
5 amount determined under subsection
6 (b) for the fiscal year, exclusive of the
7 adjustment under this paragraph for
8 such fiscal year; and

9 “(II) the excess facility percent-
10 age described in clause (iii).

11 “(iii) EXCESS FACILITY PERCENT-
12 AGE.—The excess facility percentage de-
13 scribed in this clause is—

14 “(I) the amount by which the av-
15 erage number of OTC monograph
16 drug facilities subject to a facility fee
17 under subsection (a)(1) over the pre-
18 ceding 3 fiscal years exceeds 1,625;
19 divided by

20 “(II) 1,625.

21 “(5) ANNUAL FEE SETTING.—The Secretary
22 shall, not later than 60 days before the first day of
23 each fiscal year—

24 “(A) establish for such fiscal year, based
25 on the revenue amounts under subsection (b)

1 and the adjustments provided under this sub-
2 section—

3 “(i) OTC monograph drug facility fees
4 under subsection (a)(1); and

5 “(ii) OTC monograph order request
6 fees under subsection (a)(2); and

7 “(B) publish such fee revenue amounts, fa-
8 cility fees, and OTC monograph order request
9 fees in the Federal Register.”.

10 (d) CREDITING AND AVAILABILITY OF FEES.—Sec-
11 tion 744M(f) of the Federal Food, Drug, and Cosmetic
12 Act (21 U.S.C. 379j–72(f)) is amended—

13 (1) in paragraph (2)(D)—

14 (A) in the subparagraph heading, by strik-
15 ing “IN SUBSEQUENT YEARS”; and

16 (B) by striking “(after fiscal year 2021)”;
17 and

18 (2) in paragraph (3), by striking “2021
19 through 2025” and inserting “2026 through 2030”.

20 **SEC. 6505. REAUTHORIZATION; REPORTING REQUIRE-**
21 **MENTS.**

22 (a) PERFORMANCE REPORT.—Section 744N of the
23 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
24 73) is amended—

25 (1) in subsection (a)—

1 (A) by striking “Beginning with fiscal year
2 2021, and not later than 120 calendar days
3 after the end of each fiscal year thereafter” and
4 inserting the following:

5 “(1) IN GENERAL.—Not later than 120 cal-
6 endar days after the end of each fiscal year”;

7 (B) by striking “section 3861(b) of the
8 CARES Act” and inserting “section 6502 of
9 the Over-the-Counter Monograph Drug User
10 Fee Amendments”; and

11 (C) by adding at the end the following:

12 “(2) ADDITIONAL INFORMATION.—Beginning
13 with fiscal year 2026, the annual report under this
14 subsection shall include—

15 “(A) the progress of the Food and Drug
16 Administration in achieving the goals, and fu-
17 ture plans for meeting the goals, including—

18 “(i) the number of Tier 1 OTC mono-
19 graph order requests for which a proposed
20 order was issued, and the number of such
21 requests for which a final order was issued,
22 in the previous fiscal year;

23 “(ii) the number of Tier 2 OTC
24 monograph order requests for which a pro-
25 posed order was issued, and the number of

1 such requests for which a final order was
2 issued, in the previous fiscal year;

3 “(iii) the number of specified safety
4 OTC monograph order requests for which
5 a proposed order was issued, and the num-
6 ber of such requests for which a final order
7 was issued, in the previous fiscal year;

8 “(iv) the number of generally recog-
9 nized as safe and effective finalization
10 OTC monograph order requests for which
11 a proposed order was issued, and the num-
12 ber of such requests for which a final order
13 was issued, in the previous fiscal year;

14 “(v) the average timeline for proc-
15 essing OTC monograph order requests, in
16 the aggregate and by submission type, in
17 the previous fiscal year; and

18 “(vi) postmarket safety activities with
19 respect to OTC monograph drugs, includ-
20 ing—

21 “(I) collecting, developing, and
22 reviewing safety information on OTC
23 monograph drugs, including adverse
24 event reports;

1 “(II) developing and using im-
2 proved analytical tools, adverse event
3 data-collection systems, including in-
4 formation technology systems, to as-
5 sess potential safety problems, includ-
6 ing access to external databases; and

7 “(III) activities under section
8 760;

9 “(B) information regarding registration of
10 OTC monograph drug facilities and contract
11 manufacturing organization facilities and pay-
12 ment of registration fees by such facilities, in-
13 cluding—

14 “(i) the OTC monograph drug facili-
15 ties and contract manufacturing organiza-
16 tion facilities that were first registered
17 under section 510(c) or 510(i) in the fiscal
18 year; and

19 “(ii) for each OTC monograph drug
20 facility and contract manufacturing organi-
21 zation facility that was assessed a facility
22 fee under section 744M(a) in the fiscal
23 year, whether the facility paid such fee;

24 “(C) the status of implementation of evi-
25 dence and testing standards under section

1 505G(r) for nonprescription drugs intended for
2 topical administration, including—

3 “(i) the application of evidence or
4 testing standards; and

5 “(ii) the number of active ingredient
6 requests for nonprescription drugs in-
7 tended for topical administration reviewed
8 using the standards under section
9 505G(b); and

10 “(D) the progress of the Food and Drug
11 Administration in allowing nonclinical testing
12 alternatives to animal testing for the consider-
13 ation of sunscreen active ingredients.

14 “(3) CONFIDENTIALITY.—Nothing in para-
15 graph (2) shall be construed to authorize the disclo-
16 sure of information that is prohibited from disclo-
17 sure under section 301(j) of this Act or section 1905
18 of title 18, United States Code, or that is subject to
19 withholding under section 552(b)(4) of title 5,
20 United States Code.”;

21 (2) in subsection (b), by striking “fiscal year
22 2021 and each subsequent fiscal year” and inserting
23 “each fiscal year”; and

24 (3) in subsection (d)—

1 (A) by striking “2025” each place it ap-
2 pears and inserting “2030”; and

3 (B) by adding at the end the following:

4 “(4) MINUTES OF NEGOTIATION MEETINGS.—

5 “(A) PUBLIC AVAILABILITY.—The Sec-
6 retary shall make publicly available, on the pub-
7 lic website of the Food and Drug Administra-
8 tion, robust written minutes of all negotiation
9 meetings conducted under this subsection be-
10 tween the Food and Drug Administration and
11 the regulated industry, not later than 30 days
12 after each such negotiation meeting.

13 “(B) CONTENT.—The robust written min-
14 utes described under subparagraph (A) shall
15 contain, in detail, any substantive proposal
16 made by any party to the negotiations as well
17 as significant controversies or differences of
18 opinion during the negotiations and their reso-
19 lution.”.

20 (b) GAO REPORT.—

21 (1) IN GENERAL.—Not later than September
22 30, 2027, the Comptroller General of the United
23 States shall submit to the Committee on Health,
24 Education, Labor, and Pensions of the Senate and
25 the Committee on Energy and Commerce of the

1 House of Representatives a report assessing the sup-
2 ply chain of over-the-counter monograph drugs.

3 (2) CONTENTS.—The report required under
4 paragraph (1) shall include an assessment of—

5 (A) the overall stability of the supply chain
6 of over-the-counter monograph drugs;

7 (B) what information is collected by the
8 Food and Drug Administration with respect to
9 the supply chain of over-the-counter monograph
10 drugs;

11 (C) how the Food and Drug Administra-
12 tion uses information collected on the supply
13 chain of over-the-counter monograph drugs to
14 inform regulatory decisions;

15 (D) how the Food and Drug Administra-
16 tion coordinates with other Federal agencies to
17 monitor and mitigate disruptions to the supply
18 chain of over-the-counter monograph drugs; and

19 (E) the unique characteristics of the over-
20 the-counter monograph drug marketplace and
21 what additional authorities or information the
22 Food and Drug Administration may need to en-
23 sure the stability of the supply chain of over-
24 the-counter monograph drugs.

1 **SEC. 6506. TREATMENT OF ACTIVE INGREDIENTS FOR TOP-**
2 **ICAL ADMINISTRATION.**

3 (a) IN GENERAL.—Section 505G of the Federal
4 Food, Drug, and Cosmetic Act (21 U.S.C. 355h) is
5 amended by adding at the end the following:

6 “(r) EVIDENCE AND TESTING STANDARDS FOR AC-
7 TIVE INGREDIENTS FOR TOPICAL ADMINISTRATION.—

8 “(1) EVIDENCE AND TESTING STANDARDS FOR
9 ACTIVE INGREDIENTS FOR TOPICAL ADMINISTRA-
10 TION.—The Secretary shall—

11 “(A) in evaluating the generally recognized
12 as safe and effective status of active ingredients
13 used in nonprescription drugs intended for top-
14 ical administration for purposes of subsection
15 (a), utilize standards that allow for the use of
16 real world evidence (as defined in section
17 505F(b)), as appropriate, as part of a com-
18 prehensive evaluation of scientific evidence to
19 demonstrate the safety and effectiveness of such
20 active ingredients, to supplement evidence from
21 traditional clinical trials, provided that such
22 standards allow the Secretary to evaluate
23 whether the benefits of such active ingredients
24 outweigh the risks; and

1 “(B) apply subsection (b)(6)(C) to the reg-
2 ulation of active ingredients used in drugs in-
3 tended for topical administration.

4 “(2) NON-ANIMAL TESTING METHODS FOR TOP-
5 ICAL ACTIVE INGREDIENTS.—

6 “(A) IN GENERAL.—The Secretary shall
7 consider the types of nonclinical tests described
8 in paragraphs (1) through (4) of the first sub-
9 section (z) of section 505 (as inserted by sec-
10 tion 3209(a)(2) of the Health Extenders, Im-
11 proving Access to Medicare, Medicaid, and
12 CHIP, and Strengthening Public Health Act of
13 2022 (division FF of Public Law 117–328)), or
14 any other alternative to animal testing that the
15 Secretary determines appropriate, in the consid-
16 eration of drugs intended for topical adminis-
17 tration under this section.

18 “(B) GUIDANCE.—Not later than 1 year
19 after the date of enactment of this subsection,
20 the Secretary shall issue new draft guidance on
21 how sponsors can use nonclinical testing alter-
22 natives to animal testing, as appropriate, to
23 meet safety and efficacy standards under this
24 section for drugs intended for topical adminis-
25 tration.

1 “(3) CLARIFICATION.—Nothing in this sub-
2 section shall be construed to alter, supersede, or
3 limit the standards for making determinations of
4 whether a drug is generally recognized as safe and
5 effective under section 201(p) or the standards set
6 forth under section 505 for determining the safety
7 and effectiveness of drugs.”.

8 (b) SUNSCREEN FINAL ADMINISTRATIVE ORDER.—
9 A final administrative order on nonprescription sunscreen
10 active ingredients issued under section 3854 of the
11 Coronavirus Aid, Relief, and Economic Security Act (Pub-
12 lic Law 116–136; 21 U.S.C. 360fff–3 note) shall—

13 (1) account for historical data regarding the
14 safety of sunscreen active ingredients that have pre-
15 viously been accepted for marketing in the United
16 States;

17 (2) account for the role of broad spectrum sun-
18 screens with a Sun Protection Factor of 15 or high-
19 er in effective skin cancer prevention; and

20 (3) incorporate the evidence and testing stand-
21 ards for sunscreen active ingredients detailed in sec-
22 tion 505G(r) of the Federal Food, Drug, and Cos-
23 metic Act (21 U.S.C. 355h) (as added by subsection
24 (a)).

1 **SEC. 6507. INCREASING THE CLARITY AND PREDICT-**
2 **ABILITY OF THE PROCESS FOR DEVELOPING**
3 **APPLICATIONS FOR RX-TO-NONPRESCRIP-**
4 **TION SWITCHES.**

5 (a) IN GENERAL.—Section 505(b) of the Federal
6 Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is
7 amended by adding at the end the following:

8 “(7) RX-TO-NONPRESCRIPTION SWITCHES.—

9 “(A) MEETINGS.—Any person planning to
10 submit an application for an Rx-to-nonprescrip-
11 tion switch may submit to the Secretary a writ-
12 ten request for a meeting, for purposes of devel-
13 oping a plan for such application that addresses
14 the potential risks to public health of such
15 switch and the evidence necessary to support
16 such application, including the design of any
17 necessary studies, and the format and content
18 of the planned application. The Secretary may
19 grant such a meeting, as appropriate, consistent
20 with established procedures for granting meet-
21 ings with, and providing written responses to,
22 applications under this section. Each such
23 meeting shall be documented in meeting min-
24 utes.

25 “(B) GUIDANCE.—

1 “(i) IN GENERAL.—Not later than 18
2 months after the date of enactment of this
3 paragraph, the Secretary shall issue guid-
4 ance to increase the clarity and predict-
5 ability of the process and standards for ap-
6 proval of applications for nonprescription
7 drugs under this section, including in the
8 case of applications for an Rx-to-non-
9 prescription switch, especially with respect
10 to prescription drugs with well-established
11 safety profiles for which an applicant may
12 seek approval for nonprescription use.

13 “(ii) CONTENTS.—The guidance
14 under clause (i) shall—

15 “(I) describe how published re-
16 ports in medical literature, any pre-
17 vious finding of safety or effectiveness
18 for the drug under this section, the
19 results of significant human experi-
20 ence with the drug, unpublished stud-
21 ies and other data, and other sources
22 of information may be used to support
23 an application for a nonprescription
24 drug, including in the context of an

1 application for an Rx-to-nonprescrip-
2 tion switch;

3 “(II) set forth procedures for
4 sponsors to request meetings de-
5 scribed in subparagraph (A) and doc-
6 ument the recommendations made in
7 such meetings;

8 “(III) describe evidentiary expec-
9 tations to support approval of an ap-
10 plication for a nonprescription drug,
11 including in the context of an applica-
12 tion for an Rx-to-nonprescription
13 switch, including how sponsors can
14 demonstrate that consumers can ap-
15 propriately self-select and use the
16 drug and comprehend the non-
17 prescription drug label; and

18 “(IV) provide recommendations
19 for how mechanisms, in addition to
20 the required Drug Facts Label, such
21 as mobile applications and decisions
22 aids, can be incorporated into the in-
23 formation submitted in support of an
24 application for an Rx-to-nonprescrip-
25 tion switch.

1 “(C) PLAN TO ENGAGE WITH STAKE-
2 HOLDERS.—Not later than 1 year after the
3 date of enactment of this paragraph, the Sec-
4 retary shall develop and make publicly available
5 on the website of the Food and Drug Adminis-
6 tration a plan to engage stakeholders on steps
7 and factors for application holders and other
8 stakeholders to consider in identifying approved
9 prescription drugs that may be promising can-
10 didates for applications for an Rx-to-non-
11 prescription switch.

12 “(D) DEFINITION.—For purposes of this
13 paragraph, the term ‘Rx-to-nonprescription
14 switch’ means the approval of an application, or
15 supplemental application, as applicable, sub-
16 mitted under this section by the holder of an
17 approved application for a prescription drug
18 seeking approval to market such drug as a non-
19 prescription drug, including for—

20 “(i) a full Rx-to-nonprescription
21 switch, under which a drug previously ap-
22 proved for prescription use only is—

23 “(I) approved for nonprescription
24 use under the same conditions as ap-

1 plied to the drug when approved for
2 prescription use; or

3 “(II) approved for nonprescrip-
4 tion use subject to one or more addi-
5 tional conditions for nonprescription
6 use; and

7 “(ii) a partial Rx-to-nonprescription
8 switch, under which the drug is approved
9 for nonprescription use only under certain
10 conditions described in the approved label-
11 ing, while the drug otherwise remains ap-
12 proved for prescription use only.

13 “(E) RULE OF CONSTRUCTION.—Nothing
14 in this paragraph shall be construed to—

15 “(i) supersede or modify the authority
16 of the Secretary under section 505G with
17 respect to the regulation of OTC mono-
18 graph drugs; or

19 “(ii) authorize the disclosure by the
20 Secretary of confidential commercial infor-
21 mation or trade secrets.”.

22 (b) GAO REPORT.—

23 (1) IN GENERAL.—Not later than 1 year after
24 the date of enactment of this Act, the Comptroller
25 General of the United States shall submit to the

1 Committee on Health, Education, Labor, and Pen-
2 sions of the Senate and the Committee on Energy
3 and Commerce of the House of Representatives a re-
4 port that evaluates—

5 (A) the number of applications for an Rx-
6 to-nonprescription switch approved during the
7 period beginning on October 1, 2022, and end-
8 ing on the date of the report;

9 (B) the number of drugs for which an ap-
10 plication for an Rx-to-nonprescription switch
11 was approved during such period subject to an
12 additional condition for nonprescription use;

13 (C) among the drugs for which an applica-
14 tion for a full or partial Rx-to-nonprescription
15 switch was approved during such period, the av-
16 erage length of time from receipt by the Food
17 and Drug Administration of the application to
18 the approval of such application;

19 (D) the number of partial Rx-to-non-
20 prescription switch applications approved dur-
21 ing such period, and the number of applications
22 for such a partial switch not approved;

23 (E) any barriers to timely and predictable
24 review of applications for an Rx-to-nonprescrip-
25 tion switch;

1 (F) engagement by the Food and Drug
2 Administration with public stakeholders, includ-
3 ing public meetings or additional activities to
4 support review of applications for an Rx-to-non-
5 prescription switch; and

6 (G) opportunities for collaboration between
7 the Center for Drug Evaluation and Research
8 and the Centers for Medicare & Medicaid Serv-
9 ices for the purpose of analyzing health insur-
10 ance claims data for commonly prescribed drugs
11 that appear to be suitable for an Rx-to-non-
12 prescription switch.

13 (2) DEFINITION.—In this subsection, the term
14 “Rx-to-nonprescription switch” has the meaning
15 given such term in paragraph (7) of section 505(b)
16 of the Federal Food, Drug, and Cosmetic Act (21
17 U.S.C. 244(b)), as added by subsection (a).

18 **SEC. 6508. REGULATION OF CERTAIN NONPRESCRIPTION**
19 **DRUGS THAT ARE MARKETING WITHOUT AN**
20 **APPROVED DRUG APPLICATION.**

21 (a) DEVELOPMENT ADVICE TO SPONSORS OR RE-
22 QUESTORS.—Section 505G(h) of the Federal Food, Drug,
23 and Cosmetic Act (21 U.S.C. 355h(h)) is amended by
24 striking “sponsors or requestors” and inserting “sponsors,

1 requestors, or organizations nominated by sponsors or re-
2 questors to represent their interests in a proceeding”.

3 (b) TECHNICAL CORRECTION.—Section
4 505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and
5 Cosmetic Act (21 U.S.C. 355h(b)(2)(A)(iv)(III)) is
6 amended by striking “requestors” and inserting “sponsors
7 or requestors”.

8 **SEC. 6509. SUNSET DATES.**

9 (a) AUTHORIZATION.—Sections 744L and 744M of
10 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
11 379j–71; 379j–72) shall cease to be effective October 1,
12 2030.

13 (b) REPORTING REQUIREMENTS.—Section 744N of
14 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
15 379j–73) shall cease to be effective January 31, 2031.

16 **SEC. 6510. EFFECTIVE DATE.**

17 The amendments made by this title shall take effect
18 on October 1, 2025, or the date of the enactment of this
19 Act, whichever is later, except that fees under part 10 of
20 subchapter C of chapter VII of the Federal Food, Drug,
21 and Cosmetic Act (21 U.S.C. 379j–71 et seq.) shall be
22 assessed beginning October 1, 2025, regardless of the date
23 of the enactment of this Act.

1 **SEC. 6511. SAVINGS CLAUSE.**

2 Notwithstanding the amendments made by this title,
3 part 10 of subchapter C of chapter VII of the Federal
4 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–71 et
5 seq.), as in effect on the day before the date of enactment
6 of this Act, shall continue to be in effect with respect to
7 assessing and collecting any fee required by such part for
8 a fiscal year prior to fiscal year 2026.

9 **TITLE VI—NO SURPRISES ACT**
10 **IMPLEMENTATION**

11 **SEC. 6601. EXTENDING AVAILABILITY OF FUNDING FOR NO**
12 **SURPRISES ACT IMPLEMENTATION.**

13 Section 118(a) of division BB of the Consolidated
14 Appropriations Act, 2021 (Public Law 116–260) is
15 amended—

16 (1) by striking “otherwise appropriated, to the
17 Secretary of Health and Human Services” and in-
18 serting the following: “otherwise appropriated—

19 “(1) to the Secretary of Health and Human
20 Services”;

21 (2) in paragraph (1), as so inserted, by striking
22 “September 30, 2025.” and inserting “January 30,
23 2026; and”; and

24 (3) by adding at the end the following new
25 paragraph:

1 “(2) to the Secretary of Health and Human
2 Services, in addition to amounts otherwise appro-
3 priated under paragraph (1), \$14,000,000 for the
4 period beginning on October 1, 2025, and ending on
5 January 30, 2026.”.

6 **DIVISION G—DEPARTMENT OF**
7 **VETERANS AFFAIRS EXTENDERS**
8 **TITLE I—HEALTH CARE**
9 **MATTERS**

10 **SEC. 7101. EXTENSION OF AUTHORITY FOR COLLECTION OF**
11 **COPAYMENTS FOR HOSPITAL CARE AND**
12 **NURSING HOME CARE.**

13 Section 1710(f)(2)(B) of title 38, United States
14 Code, is amended by striking “September 30, 2025” and
15 inserting “September 30, 2026”.

16 **SEC. 7102. EXTENSION OF REQUIREMENT TO PROVIDE**
17 **NURSING HOME CARE TO CERTAIN VET-**
18 **ERANS WITH SERVICE-CONNECTED DISABIL-**
19 **ITIES.**

20 Section 1710A(d) of title 38, United States Code, is
21 amended by striking “September 30, 2025” and inserting
22 “September 30, 2026”.

1 **SEC. 7103. EXTENSION OF STAFF SERGEANT PARKER GOR-**
2 **DON FOX SUICIDE PREVENTION GRANT PRO-**
3 **GRAM.**

4 Section 201(j) of the Commander John Scott
5 Hannon Veterans Mental Health Care Improvement Act
6 of 2019 (Public Law 116–171; 38 U.S.C. 1720F note)
7 is amended by striking “the date that is three years after
8 the date on which the first grant is awarded under this
9 section” and inserting “September 30, 2026”.

10 **SEC. 7104. EXTENSION OF FUNDING FOR EXPANSION OF**
11 **RURAL ACCESS NETWORK FOR GROWTH EN-**
12 **HANCEMENT PROGRAM.**

13 Section 2(d) of the Sgt. Ketchum Rural Veterans
14 Mental Health Act of 2021 (Public Law 117–21; 38
15 U.S.C. 1712A note) is amended by striking “2025” and
16 inserting “2026”.

17 **TITLE II—BENEFITS**

18 **SEC. 7201. EXTENSION OF REQUIREMENT FOR QUARTERLY**
19 **BRIEFINGS ON ADMINISTRATION OF AU-**
20 **THORITIES RELATING TO DETERMINATIONS**
21 **REGARDING PRESUMPTIONS OF SERVICE**
22 **CONNECTION BASED ON TOXIC EXPOSURE.**

23 Section 202(b)(2) of the Sergeant First Class Heath
24 Robinson Honoring our Promise to Address Comprehen-
25 sive Toxics Act of 2022 (Public Law 117–168) is amended
26 by striking “On a quarterly basis during the two-year pe-

1 riod beginning on the date of the enactment of this Act,”
2 and inserting “On a quarterly basis during the period be-
3 ginning on the date of the enactment of this Act and end-
4 ing on December 31, 2026,”.

5 **SEC. 7202. EXTENSION OF REQUIREMENT RELATING TO**
6 **RESTORATION OF ENTITLEMENT TO EDU-**
7 **CATIONAL ASSISTANCE IN CASES OF CLO-**
8 **SURE OR DISAPPROVAL OF EDUCATIONAL IN-**
9 **STITUTIONS.**

10 Section 3699(c)(2)(C) of title 38, United States
11 Code, is amended by striking “September 30, 2025” and
12 inserting “September 30, 2026”.

13 **SEC. 7203. EXTENSION OF TEMPORARY CLARIFICATION OF**
14 **LICENSURE REQUIREMENTS FOR CON-**
15 **TRACTOR MEDICAL PROFESSIONALS TO PER-**
16 **FORM MEDICAL DISABILITY EXAMINATIONS**
17 **FOR THE DEPARTMENT OF VETERANS AF-**
18 **FAIRS UNDER PILOT PROGRAM FOR USE OF**
19 **CONTRACT PHYSICIANS FOR DISABILITY EX-**
20 **AMINATIONS.**

21 Section 2002(a)(4) of the Johnny Isakson and David
22 P. Roe, M.D. Veterans Health Care and Benefits Improve-
23 ment Act of 2020 (Public Law 116–315; 38 U.S.C. 5101
24 note) is amended by striking “five years” and inserting
25 “six years”.

1 **SEC. 7204. EXTENSION OF AUTHORITY TO MAINTAIN RE-**
2 **GIONAL OFFICE IN REPUBLIC OF PHIL-**
3 **IPPINES.**

4 Section 315(b) of title 38, United States Code, is
5 amended by striking “September 30, 2025” and inserting
6 “September 30, 2026”.

7 **TITLE III—HOUSING**

8 **SEC. 7301. EXTENSION OF AUTHORIZATION OF APPROPRIA-**
9 **TIONS FOR HOMELESS WOMEN VETERANS**
10 **AND HOMELESS VETERANS WITH CHILDREN**
11 **REINTEGRATION GRANT PROGRAM.**

12 Section 2021A(f)(1) of title 38, United States Code,
13 is amended by striking “2025” and inserting “2026”.

14 **SEC. 7302. EXTENSION OF AUTHORITY FOR TREATMENT**
15 **AND REHABILITATION FOR SERIOUSLY MEN-**
16 **TALLY ILL AND HOMELESS VETERANS.**

17 (a) GENERAL TREATMENT.—Section 2031(b) of title
18 38, United States Code, is amended by striking “Sep-

19 tember 30, 2025” and inserting “September 30, 2026”.
20 (b) ADDITIONAL SERVICES AT CERTAIN LOCA-
21 TIONS.—Section 2033(d) of title 38, United States Code,
22 is amended by striking “September 30, 2025” and insert-
23 ing “September 30, 2026”.

1 **SEC. 7303. EXTENSION OF FUNDING FOR FINANCIAL AS-**
2 **SISTANCE FOR SUPPORTIVE SERVICES FOR**
3 **VERY LOW-INCOME VETERAN FAMILIES IN**
4 **PERMANENT HOUSING.**

5 Section 2044(e) of title 38, United States Code, is
6 amended by adding at the end the following new para-
7 graph:

8 “(9) \$660,000,000 for fiscal year 2026.”.

9 **SEC. 7304. EXTENSION OF FUNDING FOR GRANT PROGRAM**
10 **FOR HOMELESS VETERANS WITH SPECIAL**
11 **NEEDS.**

12 Section 2061(d)(1) of title 38, United States Code,
13 is amended by striking “2025” and inserting “2026”.

14 **SEC. 7305. EXTENSION OF AUTHORITY TO PROVIDE ASSIST-**
15 **ANCE FOR SPECIALLY ADAPTED HOUSING**
16 **FOR DISABLED VETERANS RESIDING TEMPO-**
17 **RARILY IN HOUSING OWNED BY A FAMILY**
18 **MEMBER.**

19 Section 2102A(e) of title 38, United States Code, is
20 amended by striking “September 30, 2025” and inserting
21 “September 30, 2026”.

1 **SEC. 7306. EXTENSION OF AUTHORITY FOR SPECIALLY**
2 **ADAPTED HOUSING ASSISTIVE TECHNOLOGY**
3 **GRANT PROGRAM.**

4 Section 2108(g) of title 38, United States Code, is
5 amended by striking “September 30, 2025” and inserting
6 “September 30, 2026”.

7 **SEC. 7307. IMPROVEMENTS TO PARTIAL CLAIM PROGRAM**
8 **OF THE DEPARTMENT OF VETERANS AF-**
9 **FAIRS.**

10 (a) CLARIFICATION OF RELATIONSHIP TO OTHER
11 POWERS OF SECRETARY.—Section 3720(h) of title 38,
12 United States Code, is amended by striking “of subsection
13 (a)” and all that follows through the period at the end
14 and inserting “of subsection (a) in conjunction with the
15 purchase of a loan under section 3732(a)(2) of this title
16 unless the Secretary determines the purchase would be
17 made consistent with section 3732(d) of this title.”.

18 (b) ADMINISTRATION OF PARTIAL CLAIM PRO-
19 GRAM.—Section 3737 of such title is amended—

20 (1) in subsection (b)(2), by striking “first lien
21 guaranteed loan for such property” and inserting
22 “amount of indebtedness under the guaranteed loan
23 that the Secretary does not purchase”; and

24 (2) in subsection (c)—

25 (A) in paragraph (2)(B)(ii), by striking
26 “120 days” and inserting “180 days”; and

1 (B) by amending paragraph (3) to read as
2 follows:

3 “(3) An amount paid to the holder of a loan as a
4 partial claim—

5 “(A) shall not alter the guaranty calculation
6 specified by section 3703 of this title;

7 “(B) shall be included, for the purpose of a liq-
8 uidation sale, in the same manner as any other ad-
9 vance allowed by the Secretary; and

10 “(C) shall not be claimed under the guaranty or
11 increase the Secretary’s cost of acquisition of the
12 property securing the defaulted loan.”.

13 (c) REQUIREMENTS OF LOAN HOLDER.—Section
14 (d)(1) of such section is amending by inserting “and serv-
15 icing the loan” after “documents”.

16 (d) DEFAULT AND FORECLOSURE.—Subsection (e)
17 of such section is amended—

18 (1) in paragraph (1)—

19 (A) in subparagraph (A), by striking “an
20 individual who” and all that follows through the
21 period at the end and inserting the following:
22 “a borrower who defaults on a partial claim
23 shall be liable to the Secretary for any loss suf-
24 fered by the Secretary with respect to such de-
25 fault, and such loss may be recovered in the

1 same manner as any other debt due the United
2 States. The Secretary shall not restore housing
3 loan entitlement under section 3702(b) of this
4 title until such loss is repaid in full.”; and

5 (B) by amending subparagraph (B) to read
6 as follows:

7 “(B) The Secretary may charge administrative costs,
8 fees, and interest, as appropriate, with respect to any de-
9 fault under a partial claim in a manner similar to the in-
10 terest and administrative costs charged under section
11 5315 of this title.”; and

12 (2) by amending paragraph (2) to read as fol-
13 lows:

14 “(2) Notwithstanding section 2410 of title 28, a non-
15 judicial sale of real property to satisfy a loan guaranteed
16 under this chapter shall discharge the property from a
17 partial claim interest held by the Secretary, provided that
18 the holder of the guaranteed loan conducts the non-judi-
19 cial sale and distributes the sale proceeds, if any, in ac-
20 cordance with the State or local law where such property
21 is situated.”.

22 (e) GUIDANCE IN ADVANCE OF REGULATIONS.—Sub-
23 section (h) of such section is amended to read as follows:

24 “(h) GUIDANCE IN ADVANCE OF REGULATIONS.—
25 Notwithstanding any other provision of law, the Secretary

1 may, before prescribing regulations, issue administrative
2 guidance with respect to the Partial Claim Program under
3 this section and the loss mitigation options prescribed
4 under section 3732(d) of this title, including any addi-
5 tional terms, conditions, and requirements the Secretary
6 determines necessary.”.

7 **SEC. 7308. GOVERNMENT ACCOUNTABILITY OFFICE RE-**
8 **PORTS ON PARTIAL CLAIM PROGRAM OF THE**
9 **DEPARTMENT OF VETERANS AFFAIRS AND**
10 **OTHER MATTERS.**

11 (a) ANNUAL REPORTS.—

12 (1) IN GENERAL.—Not later than one year
13 after the date of the enactment of this Act, and
14 every year thereafter until the Partial Claim Pro-
15 gram terminates, the Comptroller General of the
16 United States shall submit to the Committee on Vet-
17 erans’ Affairs of the Senate and the Committee on
18 Veterans’ Affairs of the House of Representatives a
19 report.

20 (2) ELEMENTS.—Each report required by para-
21 graph (1) shall include, for the period covered by the
22 report and disaggregated by quarter, the following:

23 (A) Key data on the performance of the
24 Partial Claim Program, including—

1 (i) the number of partial claims filed
2 and approved; and

3 (ii) the redefault and foreclosure rates
4 of loans for which a partial claim was
5 made.

6 (B) A comparison of the data described in
7 subparagraph (A) with data on the performance
8 of other loss mitigation options provided by the
9 Department of Veterans Affairs.

10 (C) The number of housing loans insured,
11 guaranteed, or made by the Secretary of Vet-
12 erans Affairs under chapter 37 of title 38,
13 United States Code.

14 (D) The number of applications for hous-
15 ing loan benefits under such chapter denied.

16 (E) The number of housing loans insured,
17 guaranteed, or made by the Secretary under
18 such chapter refinanced under section
19 3710(a)(8) or 3712 of title 38, United States
20 Code.

21 (F) The number of veterans who owe a
22 payment on a mortgage associated with a loan
23 insured, guaranteed, or made by the Secretary
24 under such chapter that is at least—

25 (i) 60 days late; and

1 (ii) 90 days late.

2 (b) ASSESSMENT.—

3 (1) IN GENERAL.—Not later than one year be-
4 fore the Partial Claim Program terminates, the
5 Comptroller General shall—

6 (A) conduct an assessment of the benefits
7 and challenges of the Partial Claim Program;
8 and

9 (B) submit to the Committee on Veterans'
10 Affairs of the Senate and the Committee on
11 Veterans' Affairs of the House of Representa-
12 tives a report on the findings of the Comptroller
13 General with respect to that assessment.

14 (2) CONSIDERATIONS.—In conducting the as-
15 sessment required by paragraph (1), the Comptroller
16 General shall consider the following:

17 (A) The characteristics of borrowers for
18 whom a partial claim was made compared to
19 the characteristics of borrowers provided other
20 loss mitigation options by the Department of
21 Veterans Affairs.

22 (B) The performance of loans guaranteed
23 under chapter 37 of title 38, United States
24 Code, following various loss mitigation actions.

1 (C) The information the Department con-
2 sidered in determining whether a borrower
3 would benefit from a partial claim compared to
4 other loss mitigation options.

5 (D) The costs to taxpayers of the Partial
6 Claim Program compared to the costs of other
7 loss mitigation options provided by the Depart-
8 ment.

9 (E) Any similarities and differences in the
10 Department's administration and use of the
11 Partial Claim Program compared to the De-
12 partment's administration and use of the
13 COVID-19 Veterans Assistance Partial Claim
14 Payment program established under subpart F
15 of part 36 of title 38, Code of Regulations.

16 (F) The information the Department
17 learned from the COVID-19 Veterans Assist-
18 ance Partial Claim Payment program and the
19 extent to which those lessons learned were ap-
20 plied to the Partial Claim Program.

21 (G) The types of information the Depart-
22 ment collected to monitor the performance and
23 effectiveness of the Partial Claim Program and
24 how the Department used that information to
25 make any needed adjustments to the program.

1 (H) How the use by the Department of
2 partial claims compares to the use of partial
3 claims by other Federal housing agencies, in-
4 cluding, for each partial claim program—

5 (i) the volume of loans for which par-
6 tial claims have been made;

7 (ii) the results for borrowers (includ-
8 ing redefault and foreclosure rates); and

9 (iii) the costs to taxpayers.

10 (c) PARTIAL CLAIM PROGRAM DEFINED.—In this
11 section, the term “Partial Claim Program” means the
12 Partial Claim Program of the Department of Veterans Af-
13 fairs carried out under section 3737 of title 38, United
14 States Code.

15 **TITLE IV—OTHER MATTERS**

16 **SEC. 7401. EXTENSION OF SUBPOENA AUTHORITY OF IN-**
17 **SPECTOR GENERAL OF DEPARTMENT OF**
18 **VETERANS AFFAIRS.**

19 Section 312(d)(7)(A) of title 38, United States Code,
20 is amended by striking “September 30, 2025” and insert-
21 ing “September 30, 2026”.

1 **SEC. 7402. EXTENSION OF REQUIREMENT FOR ANNUAL RE-**
2 **PORT ON USE OF AUTHORITY TO PROVIDE**
3 **EQUITABLE RELIEF.**

4 Section 503(c) of title 38, United States Code, is
5 amended by striking “December 31, 2025” and inserting
6 “December 31, 2026”.

7 **SEC. 7403. EXTENSION OF AUTHORITY FOR SECRETARY OF**
8 **VETERANS AFFAIRS TO TRANSPORT INDIVID-**
9 **UALS TO AND FROM FACILITIES OF DEPART-**
10 **MENT OF VETERANS AFFAIRS.**

11 Section 111A(a)(2) of title 38, United States Code,
12 is amended by striking “September 30, 2025” and insert-
13 ing “September 30, 2026”.

14 **SEC. 7404. EXTENSION OF AUTHORITY RELATING TO VEND-**
15 **EE LOAN PROGRAM.**

16 Section 3733(a)(8) of title 38, United States Code,
17 is amended—

18 (1) in the matter preceding subparagraph (A),
19 by striking “September 30, 2025” and inserting
20 “September 30, 2026”; and

21 (2) in subparagraph (C), by striking “Sep-
22 tember 30, 2025” and inserting “September 30,
23 2026”.

1 **SEC. 7405. EXTENSION OF AUTHORITY FOR TRANSFER OF**
2 **REAL PROPERTY.**

3 Section 8118(a)(5) of title 38, United States Code,
4 is amended by striking “September 30, 2025” and insert-
5 ing “September 30, 2026”.

6 **SEC. 7406. RETROACTIVE EFFECTIVE DATE.**

7 The amendments made by this division, except for the
8 amendments made by section 7307, shall take effect as
9 if enacted on September 30, 2025.

10 **DIVISION H—MISCELLANEOUS**

11 **SEC. 8001. BUDGETARY EFFECTS.**

12 (a) **STATUTORY PAYGO SCORECARDS.**—The budg-
13 etary effects of this division and divisions E through G
14 shall not be entered on either PAYGO scorecard main-
15 tained pursuant to section 4(d) of the Statutory Pay-As-
16 You-Go Act of 2010.

17 (b) **SENATE PAYGO SCORECARDS.**—The budgetary
18 effects of this division and divisions E through G shall
19 not be entered on any PAYGO scorecard maintained for
20 purposes of section 4106 of H. Con. Res. 71 (115th Con-
21 gress).

22 (c) **CLASSIFICATION OF BUDGETARY EFFECTS.**—
23 Notwithstanding Rule 3 of the Budget Scorekeeping
24 Guidelines set forth in the joint explanatory statement of
25 the committee of conference accompanying Conference Re-
26 port 105–217 and section 250(c)(8) of the Balanced

1 Budget and Emergency Deficit Control Act of 1985, the
2 budgetary effects of this division and divisions E through
3 G shall not be estimated—

4 (1) for purposes of section 251 of such Act;

5 (2) for purposes of an allocation to the Com-
6 mittee on Appropriations pursuant to section 302(a)
7 of the Congressional Budget Act of 1974; and

8 (3) for purposes of paragraph (4)(C) of section
9 3 of the Statutory Pay-As-You-Go Act of 2010 as
10 being included in an appropriation Act.

11 (d) BALANCES ON THE PAYGO SCORECARDS.—Ef-
12 fective on the date of the adjournment of the first session
13 of the 119th Congress, and for the purposes of the annual
14 report issued pursuant to section 5 of the Statutory Pay-
15 As-You-Go Act of 2010 (2 U.S.C. 934) after such ad-
16 journment and for determining whether a sequestration
17 order is necessary under such section, the balances on the
18 PAYGO scorecards established pursuant to paragraphs
19 (4) and (5) of section 4(d) of such Act shall be zero.